Discover the FlexShares Quality Dividend Defensive Index Fund (QDEF) for potential capital gains with limited volatility and ...

According to the last reported balance sheet, AbbVie had liabilities of US$41.9b due within 12 months, and liabilities of ...

AbbVie Inc. closed $6.48 below its 52-week high ($199.95), which the company reached on September 3rd.

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with ...

AbbVie (ABBV) announced the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion ...

Jim Cramer said during his latest program on CNBC that the Federal Reserve wanted to contain inflation and make sure it’s ...

Elahere, which won initial U.S. Food and Drug Administration approval in 2022 for platinum-resistant ovarian cancer, was the key asset in AbbVie's $10.1 billion acquisition of biotech ImmunoGen that ...

This Acquisition Enhances PRN Physician Recommended Nutriceuticals' ("PRN") Product Portfolio of Science-Based Eye Health Products ...

Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the marketing authorization of mirvetuximab soravtansine (ELAHERE®) for the ...

We recently compiled a list titled Jim Cramer’s Top Stock Picks: 10 Stocks with High Potential. In this article, we will have ...

Bausch Health is rumored to be looking to sell its Bausch + Lomb business, which will ease bankruptcy concerns and upgrade ...